Acadia Pharmaceuticals Court & Legal Update
The U.S. District Court for the Southern District of California has granted preliminary approval for a settlement of a stockholder derivative action against Acadia Pharmaceuticals and certain of its officers and directors. The settlement resolves claims related to the company's drug pimavanserin (NUPLAZID) and includes the implementation of corporate governance reforms and the payment of plaintiff attorney fees. A final settlement hearing is scheduled for January 13, 2027.
- Counterparty
- Kanner et al.